NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
Arvinas, Inc. ARVN
9 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$262.6M
▼ 0.3% vs FY2024
EPS · FY25
$-1.14
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-16.2%
Net margin · FY25
-30.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 262.6M
Revenue, FY2025 · full 9-year series below
Revenue
Net income
The company lost 31 cents on every revenue dollar this year.
Per share
USD -1.14
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-16.2%
Return on equity, FY2025
ROE
Operating margin-45.1%
Net margin-30.8%
Return on assets-8.9%
Each USD of equity lost 16 cents this year.
Returned to shareholders
USD 91.9M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 91.9M
Share of profit-113.7%
Consecutive raises—
USD 91.9M in buybacks went back to shareholders in a year without profit.
Growth
+58.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+26.0%
+58.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.06B
Shares outstanding, FY2025
Change, 5 years+30.9%
Change, 10 years—
The share count grew 31% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 717.9M
total assets, end of FY2025
Total assetsUSD 717.9M
EquityUSD 433.9M
CashUSD 142.9M
Gross debtUSD 600,000.00
Net debtUSD -142.3M
Current ratio4.92×
The company holds more cash than debt.
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue $B
0.3
0.3
0.1
0.1
0.1
0.0
0.0
0.0
0.0
Operating income $B
−0.1
−0.3
−0.4
−0.3
−0.2
−0.1
−0.1
−0.0
−0.0
EBITDA $B
·
−0.2
−0.4
−0.3
−0.2
−0.1
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
−0.1
−0.2
−0.4
−0.3
−0.2
−0.1
−0.1
−0.0
−0.0
EPS, diluted $
−1.14
−2.77
−6.62
−5.31
−3.82
−3.02
−2.13
−25.45
−15.08
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
−16.2
−32.6
−60.0
−42.0
−26.8
−27.5
−38.7
−110.1
·
Shares out B
0.06
0.07
0.07
0.05
0.05
0.05
0.04
0.03
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
27 of 27
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed